• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    BioVersys Gets EIB Funds to Address Antimicrobial Resistance

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Quotient Sciences

    Almac Group

    Alcami

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Syngene

    Reed-Lane

    Adare Pharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Biosimilars Improving Efficiency, Cost for All Biologics

    ...

    Related CONTENT
    • The Ever-Evolving World of Combination Products
    • Embedding Your Drug Strategy Within a Solid Foundation for Success
    • Sepha Launches Small Batch Contract Packaging Service
    • A Potential “Marriage”
    • Injectables Firms Expand Capacity
    Eric S. Langer and Ronald A. Rader, BioPlan Associates04.01.15
    Now that the FDA has just approved its first product under biosimilar regulations—Zarxio—containing filgrastim (G-CSF), a biosimilar version of Neupogen from Amgen, we can expect some more rapid shifts in the market. Factors like how this new class of biopharmaceuticals will be marketed, priced, reimbursed, defined, and even manufactured will eventually resolve. But, as with small molecule generics, efficiency in manufacturing will be critical. And how these complex, costly biologics will be produced is still not entirely obvious.

    In fact, our 12th Annual Report on Biopharmaceutical Manufacturing1 indicates that, even when innovators produce a new biologic, manufacturing efficiency and productivity are the most critical factors in manufacturing strategy, as noted by 17% of global industry respondents.  And when we consider all cost- or efficiency-related factors, fully 28% of the industry believes this is a top priority for all biologics manufacturers; biosimilars are certain to be even more efficiency-centric.

    It is reasonable, then, to expect that strategic manufacturing decisions for biosimilars will be based on cost efficiency, whether that be in-house, by captive CMO, subsidiary, or traditional CMO outsourcing.

    Biosimilars Pipeline: Many Products and Players
    There are nearly 700 cGMP-level, major-market biosimilars in various stages of development; and over 500 companies already involved globally, whether as developer, partner and/or marketer2. There are over 150 recombinant reference products for biosimilars to emulate, including about 40 with sales in the blockbuster (>$1 billion/year) revenue range3. Even just 10% of a $1 billion market, $100 million/year, could be enough for biosimilars to be profitable. In this context, with biosimilars essentially being market opportunities, and not critical high-profit innovative products, it increasingly makes sense for companies to outsource their biosimilars development and production, if it can be demonstrated cost effective.

    With biosimilars only able to enter the market after expiration of relevant patents held by others, the marketability dates for biosimilar versions of reference products can be projected. Figure 2 shows the distribution of current biopharmaceutical reference product patent expirations in the U.S. Note that the first wave of U.S. biosimilars is expected starting this year and another wave at the end of the decade, with this including an ever larger number of current blockbuster products. In just 5-10 years, there will likely be 5-10 or even more biosimilar versions, ignoring biobetters, of most eligible reference products in the U.S. market, with the total number of marketed biopharmaceuticals likely tripling by then.  The biopharmaceutical industry will look more like the overall pharmaceutical industry, with the majority of products being follow-ons.

    The majority of biosimilar developers are either Big Pharma, large generic drug, or small biotechs. And the largest and smallest companies are major users of CMOs, including for commercial manufacture. Small companies lack resources and use of CMOs is their only option.

    Typically, about 30% of marketed biopharmaceuticals are manufactured by CMOs, at some stage. This may also be expected with biosimilars. Once biosimilars become more routine, we can expect an even higher proportion to be outsourced for development and manufacturing. Now with the first U.S. biosimilars approvals, the next few years are likely to put CMOs in a good position to increase the percentage of products they develop and commercially manufacture as new biosimilar approval opportunities—patent expirations—approach.

    Biosimilars Relationship with CMOs
    Biosimilars are already having an impact on biopharmaceutical-specialist CMOs including more projects, revenue and new clients. We project an estimated 15% increase in CMO projects and revenue that will be attributed to biosimilars, mostly from biosimilar candidate development and initial bioprocess design and scale-up. This can be expected to further increase in following years as the biosimilars now in development graduate to larger scales, and as biosimilar success stories, including the first U.S. approvals, draw more players into biosimilars development.

    Although there appears to be ample capacity at all scales among CMOs to handle biosimilar manufacturing, a critical competitive issue is whether CMOs can produce biologics more efficiently than the reference products. CMOs do have an advantage in that they have exposure to multiple technologies and processes, and can access the most modern equipment and manufacturing strategies. This may improve efficiencies, especially considering that biosimilar manufacturing may be done primarily using single-use systems, and most CMOs have been adding capacity, especially single-use, in recent years4.  With single-use systems being more cost-effective and flexible, most new and, particularly, biosimilars-related capacity among CMOs involve single-use systems.
    The capacity, e.g., bioreactor size, required for biosimilar commercial manufacturing is generally on the order of a magnitude (10x) less than that of its reference product, e.g., a few 100 kg/year vs. 1000s of kg for a mAb reference product, with this facilitating use of CMOs. The majority of CMO pre-commercial manufacturing is already using single-use systems, so a similar majority of biosimilars coming to market will be commercially manufactured using single-use systems. The continuing trend for increased upstream bioprocessing titers further facilitates commercial manufacturing at smaller scales and use of single-use systems. 

    One potential trend to watch for is current reference/innovator product manufacturers using their increasingly idle bioprocessing capacity, including from growth in titers, e.g., >10,000 L mAb bioreactors now only being partially filled and/or used less frequently, to manufacture biosimilar and other products on a CMO basis. This could disrupt mainstream CMO business.

    Biosimilars will also change the structure of the biopharmaceutical CMO industry, allowing a number of CMOs to graduate to commercial cGMP product manufacturers. Biosimilars manufacturing will enable current mid-tier CMOs, e.g., $25-$125 million/year revenue, to graduate into the multi-$100 million annual revenue top tier. Currently, only a few of the largest CMOs have such revenue, e.g., Lonza and Boehringer Ingelheim, primarily from commercial product manufacturing. Commercial manufacturing is more continuous (vs. only as needed with preclinical and clinical supplies), is done at an order of magnitude larger scale, and involves comparably higher revenue and profits for CMOs compared to their usual pre-commercial work.

    In terms of geographic distribution, most biosimilar development is being done by Western/major market companies, including use of Western CMOs. These countries are the primary market for biosimilars. Biosimilar developers in developing countries are primarily involved with non-GMP biogenerics for marketing in domestic and international lesser- or non-regulated markets. Few Western-based biosimilar developers are using CMOs in developing countries, such as India and China, with some significant exceptions, e.g., Korea and Singapore. But there will be an increasing trend for developing countries to demand biopharmaceutical, including biosimilars, suppliers manufacture domestically. So, some genuine biosimilars will be manufactured, redundantly, in developing countries. 

    Biosimilars Driving Cost Efficiency
    Biosimilars are promoting adoption of newer bioprocessing technologies. Biosimilars development can be more challenging than innovative products. The requirement for products to have much the same structures, biological activities and clinical efficacy—biosimilarity—adds complexity. Analytical and bioprocessing tasks with biosimilars require trying to attain a number of preselected targets that will satisfy regulators in terms of seeing biosimilarity.  Between biosimilars being new and their having to compete against established reference and other biosimilar products, their costs and flexibility of manufacturing are critical. Thus, most biosimilars bioprocessing will likely require use of modern high-titer expression systems and manufacturing platforms, with commercial mammalian manufacturing now averaging titer of about 2.5 g/L, based on BioPlan research. 

    Improved processes for biosimilars can also bring intellectual property concerns to client-CMO relationships. For example, if a CMO has worked on a similar biosimilar for a different client, can the CMO share knowledge with the prospective client regarding how to modify its approach? Yes, CMOs are obligated to compartmentalize project knowledge; however, because CMOs are hired for their depth of experience, litigation in this area seems a possibility. 

    The CMO Biosimilars Relationship Will Change
    Biosimilars appear to be ideal products for development by CMOs capable of cost-effective production. CMOs have the process development and optimization experience, and this can also make commercial manufacturing by CMOs more attractive for clients. Developing biosimilars, in general, is likely quicker, simpler and cheaper for CMOs compared to less experienced product developers because CMOs routinely perform similar tasks. Most biopharmaceutical CMOs already have the needed and integrated bioprocessing, API and product testing, product formulation, and fill-finish capabilities. CMOs may be able to offer a quicker and more cost-effective route to biosimilars development vs. doing it fully in-house. 

    One thing that may be different between innovator and biosimilar products manufacture is that biosimilars will tend to be manufactured at a single facility, while most major innovator products are now manufactured at multiple sites or, at least, there is a backup manufacturing site. So biosimilars will have more delicate supply chains, and be more susceptible to disruptions. 

    It is also possible that some CMOs will, themselves, develop, manufacture and license-out biosimilar active agents/APIs or even finished products. Already, larger CMOs work on multiple biosimilars for different clients targeting the same reference product. The next logical step may be for CMOs to develop biosimilars themselves and offer fully-vetted APIs for licensing. This would follow the current worldwide model in generic drug APIs.

    So far, the traditional pattern of hiring different CMOs for more specialized tasks has dominated CMO involvement in biosimilars. But essentially all of the largest CMOs are already working with multiple biosimilars for clients, including biosimilars from different clients targeting the same reference product. In the future, the outsourcing of biosimilar development and production will likely go to CMOs that demonstrate lowest risk, lower costs, and greatest efficiencies. This may create a new benchmark for production efficiency for all biologics. 

    References
    1. 12th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, BioPlan Associates, Inc. Rockville, MD., April 2015, Preliminary Data,
    2. Rader, R.A., BIOPHARMA :  Biosimilars/Biobetters Pipeline Database, at www.biosimilarspipeline.com.
    3. Rader, R.A., BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets, database at www.bioplanassociates.com/publications/pub_bpuseu.htm.
    4. Langer, E.S., Rader, R.A., “Top 1000 Global Biopharmaceutical Facilities Index,” at www.top1000bio.com.

    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com; 301-921-5979  www.bioplanassociates.com

    Ronald A. Rader
    BioPlan Associates, Inc.

    Ronald A. Rader is Senior Research Director, BioPlan Associates, Inc.  He is author of BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets; and a biosimilars/biobettter pipeline-tracking database.
    Related Searches
    • API
    • cGMP
    • Outsourcing
    • Testing
    Suggested For You
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    Embedding Your Drug Strategy Within a Solid Foundation for Success Embedding Your Drug Strategy Within a Solid Foundation for Success
    Sepha Launches Small Batch Contract Packaging Service Sepha Launches Small Batch Contract Packaging Service
    A Potential “Marriage” A Potential “Marriage”
    Injectables Firms Expand Capacity Injectables Firms Expand Capacity
    Mogene Mogene
    TFF Expands Engagement with Experic TFF Expands Engagement with Experic
    India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines India Emerges as Hot Spot for Manufacturing COVID-19 Vaccines
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Vetio Animal Health Vetio Animal Health
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Current Trends in Analytical Testing Current Trends in Analytical Testing

    Related Columns

    • Biosimilars
      The Bioprocessing Trek

      The Bioprocessing Trek

      Biosimilars are the next speed-bump for CMOs
      Emil W. Ciurczak, DoraMaxx Consulting 09.16.19

    • Biosimilars
      Know the Challenges of  Biosimilar Manufacturing

      Know the Challenges of Biosimilar Manufacturing

      Best practices for a competitive market
      Jerry Martin and Michiel Ultee 09.06.17

    • Biosimilars
      Indian Generic Firms  Expand Biosimilar Portfolios

      Indian Generic Firms Expand Biosimilar Portfolios

      With more players entering the ring, the race to enter the promising biosimilars market is getting hotter by the day in India
      S. Harachand, Contributing Editor 05.09.17


    • Biosimilars
      CMOs & Biosimilars Mfg. in the U.S.

      CMOs & Biosimilars Mfg. in the U.S.

      Biosimilars are moving from novel opportunity to mainstream product
      Eric S. Langer and Ronald A. Rader, BioPlan Associates 04.20.17

    • Biosimilars

      Biosimilars Update

      Fulfilling a dire need, but at what (human) cost?
      Ben Locwin, Contributing Editor 04.03.17

    • Biosimilars | Process Development

      Contract Manufacturing Budget Trends

      Study shows where the money is, and isn’t, flowing
      Eric S. Langer, BioPlan Associates 07.12.16


    • Biosimilars | Clinical Trials | Drug Discovery | Process Development

      Like the Temperature, It Feels Like Deal Activity is Heating Up

      A summary of 2016 transactions so far
      Chad Moore, Leerink Partners LLC 05.05.16

    • Biosimilars | Clinical Trials

      Outsourced Pharma Services: 2015 Review & 2016 Outlook

      ...
      Chad Moore, Leerink Partners 01.28.16

    • APIs | Biosimilars | Clinical Trials | Process Development | Vials

      2015 in Review: 6 Key Trends Affecting CMOs

      A look at major CMO trends ranging from budgets to growth opportunities
      Eric S. Langer, BioPlan Associates 11.17.15


    • APIs | Biosimilars

      API and Intermediate Outsourcing Trends

      One thing’s for sure, when it comes to pharma trends there is no definitive trend
      Ben Locwin, Healthcare Science Advisors 10.07.15

    • Biosimilars | Fill/Finish | QA/QC

      CMOs Are Willing to Pay for More Innovation

      Downstream improvements top the list
      Eric S. Langer, BioPlan Associates 09.11.15

    • Analytical Services | APIs | Bioanalytical Services | Biosimilars | Chemistry | Clinical Trials | Excipients | GMPs/GCPs | Laboratory Testing | Microbiology | QA/QC | R&D | Regulatory Affairs | Supply Chain | Toxicology | Validation

      Inventas vitam iuvat excoluisse per artes (Let us improve life through science and art)

      But Qui bono? (Who benefits?)
      Emil W. Ciurczak, DoraMaxx Consulting 07.14.15


    • Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      Biosimilars and Their Future in Medicine

      The first step is understanding what biosimilars actually are
      Ben Locwin, Healthcare Science Advisors 06.02.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    • Biosimilars | Methods Development | Process Development | Supply Chain | Validation

      CMOs Demanding Easier-to-Integrate Single-use Devices

      Disposables’ implementation and integration critical; suppliers being put on notice
      Jean-Claude Lupis and Eric S. Langer, BioPlan Associates 05.06.15

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Executive Moves: Novavax
    • Sanofi Invests In Cutting Edge Vax Production Site In Singapore
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    Breaking News
    • BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    BIO-CAT Microbials’ OPTI-BIOME Probiotic Strain Receives FDA “Letter of No Objection” on GRAS Status
    6th Annual Dietary Supplements Regulatory Summit Scheduled for July 13
    Bunge Invests $47.5 Million in Australian Plant Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    VideoBite: Engineered Polymer Solutions
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Medtronic Introduces Extended Infusion Set in Europe
    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Contract Pharma

    Latest Breaking News From Contract Pharma

    BioVersys Gets EIB Funds to Address Antimicrobial Resistance
    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    Hallstar Beauty Names New President
    The Fragrance Foundation Announces the 2021 Awards Finalists
    Azelis Earns 'Coup de Coeur' Award at Cosmetagora 2021
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Epson SurePress reaches milestone
    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PCMC Redesigns Rx200 and Mako Clipper Wet Wipes Machines
    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login